

<b>SDS Title:</b> Mitoxantrone Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000100	<b>Page Number:</b> Page 1 of 15
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> October 03, 2024	<b>Version number:</b> 1.0

## Section 1. Identification

**GHS product identifier** : Mitoxantrone Injection, USP

**Other means of identification** : Not available.

**Product type** : Liquid.

### Relevant identified uses of the substance or mixture and uses advised against

**Product use** : Pharmaceuticals. (For intended use only.)  
Observe technical data sheet/instructions for use.  
Specific Treatments: Anticancer

**Area of application** : Professional applications.

**Supplier's details** : Meitheal Pharmaceuticals, Inc.  
8700 W. Bryn Mawr, Suite 600S  
Chicago, IL 60631

Telephone: 224-443-4617  
www.meithealpharma.com

**e-mail address of person responsible for this SDS** : info@meithealpharma.com

**Emergency telephone number (with hours of operation)** : 844-824-8426 (Monday - Friday, 08:00 - 18:00 CST)

## Section 2. Hazards identification

**OSHA/HCS status** : This material is considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200).

**Classification of the substance or mixture** : H340 GERM CELL MUTAGENICITY - Category 1  
H360 TOXIC TO REPRODUCTION - Category 1B

### GHS label elements

**Hazard pictograms** :



**Signal word** : Danger

**Hazard statements** : H340 - May cause genetic defects.  
H360 - May damage fertility or the unborn child.

### Precautionary statements

<b>SDS Title:</b> Mitoxantrone Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000100	<b>Page Number:</b> Page 2 of 15
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> October 03, 2024	<b>Version number:</b> 1.0

## Section 2. Hazards identification

- Prevention** : P201 - Obtain special instructions before use.  
P202 - Do not handle until all safety precautions have been read and understood.  
P280 - Wear protective gloves, protective clothing and eye or face protection.
- Response** : P308 + P313 - IF exposed or concerned: Get medical advice or attention.
- Storage** : P405 - Store locked up.
- Disposal** : P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.
- Hazards not otherwise classified** : None known.

## Section 3. Composition/information on ingredients

- Substance/mixture** : Mixture
- Other means of identification** : Not available.

Ingredient name	Other names	%	Identifiers
Water	-	≥90	CAS: 7732-18-5
sodium chloride	Sodium chloride	<1	CAS: 7647-14-5
1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthraquinone dihydrochloride	-	≤0.3	CAS: 70476-82-3
acetic acid	Acetic acid	≤0.1	CAS: 64-19-7
sodium acetate	-	≤0.1	CAS: 127-09-3

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

**There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.**

## Section 4. First aid measures

### Description of necessary first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
- Skin contact** : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse.

<b>SDS Title:</b> Mitoxantrone Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000100	<b>Page Number:</b> Page 3 of 15
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> October 03, 2024	<b>Version number:</b> 1.0

## Section 4. First aid measures

**Ingestion** : Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.

### Most important symptoms/effects, acute and delayed

#### Potential acute health effects

**Eye contact** : No known significant effects or critical hazards.  
**Inhalation** : No known significant effects or critical hazards.  
**Skin contact** : No known significant effects or critical hazards.  
**Ingestion** : No known significant effects or critical hazards.

#### Over-exposure signs/symptoms

**Eye contact** : No specific data.  
**Inhalation** : Adverse symptoms may include the following:  
reduced fetal weight  
increase in fetal deaths  
skeletal malformations  
**Skin contact** : Adverse symptoms may include the following:  
reduced fetal weight  
increase in fetal deaths  
skeletal malformations  
**Ingestion** : Adverse symptoms may include the following:  
reduced fetal weight  
increase in fetal deaths  
skeletal malformations

### Indication of immediate medical attention and special treatment needed, if necessary

**Notes to physician** : Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.  
**Specific treatments** : No specific treatment.  
**Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

### See toxicological information (Section 11)



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

<b>SDS Title:</b> Mitoxantrone Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000100	<b>Page Number:</b> Page 4 of 15
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> October 03, 2024	<b>Version number:</b> 1.0

## Section 5. Fire-fighting measures

### Extinguishing media

**Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.

**Unsuitable extinguishing media** : Do not use water jet.

**Specific hazards arising from the chemical** : In a fire or if heated, a pressure increase will occur and the container may burst.

**Hazardous thermal decomposition products** : No specific data.

**Special protective actions for fire-fighters** : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

**Special protective equipment for fire-fighters** : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

## Section 6. Accidental release measures

### Personal precautions, protective equipment and emergency procedures

**For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.

**For emergency responders** : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

**Environmental precautions** : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

### Methods and materials for containment and cleaning up

**Small spill** : Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

<b>SDS Title:</b> Mitoxantrone Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000100	<b>Page Number:</b> Page 5 of 15
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> October 03, 2024	<b>Version number:</b> 1.0

## Section 6. Accidental release measures

- Large spill** : Stop leak if without risk. Move containers from spill area. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product. Contain and collect spillage with non-combustible, absorbent material e. g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.

## Section 7. Handling and storage

### Precautions for safe handling

- Protective measures** : Put on appropriate personal protective equipment (see Section 8). Avoid exposure - obtain special instructions before use. Avoid exposure during pregnancy. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapor or mist. If during normal use the material presents a respiratory hazard, use only with adequate ventilation or wear appropriate respirator. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.
- Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

- Conditions for safe storage, including any incompatibilities** : Store between the following temperatures: 20 to 25°C (68 to 77°F). Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

## Section 8. Exposure controls/personal protection

### Control parameters

#### Occupational exposure limits

<b>Ingredient name</b>	<b>Exposure limits</b>
Water	None.
sodium chloride	None.
1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]	None.
anthraquinone dihydrochloride	
acetic acid	<b>ACGIH TLV (United States, 1/2024)</b> TWA 8 hours: 10 ppm. TWA 8 hours: 25 mg/m <sup>3</sup> . STEL 15 minutes: 15 ppm. STEL 15 minutes: 37 mg/m <sup>3</sup> .

<b>SDS Title:</b> Mitoxantrone Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000100	<b>Page Number:</b> Page 6 of 15
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> October 03, 2024	<b>Version number:</b> 1.0

## Section 8. Exposure controls/personal protection

sodium acetate	<p><b>NIOSH REL (United States, 10/2020)</b>  TWA 10 hours: 10 ppm.  TWA 10 hours: 25 mg/m<sup>3</sup>.  STEL 15 minutes: 15 ppm.  STEL 15 minutes: 37 mg/m<sup>3</sup>.</p> <p><b>OSHA PEL (United States, 5/2018)</b>  TWA 8 hours: 10 ppm.  TWA 8 hours: 25 mg/m<sup>3</sup>.</p> <p><b>CAL OSHA PEL (United States, 5/2018)</b>  STEL 15 minutes: 37 mg/m<sup>3</sup>.  STEL 15 minutes: 15 ppm.  C: 40 ppm.  TWA 8 hours: 25 mg/m<sup>3</sup>.  TWA 8 hours: 10 ppm.  None.</p>
----------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Appropriate engineering controls

- : If user operations generate dust, fumes, gas, vapor or mist, use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits.

### Environmental exposure controls

- : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

### Individual protection measures

#### Hygiene measures

- : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

#### Eye/face protection

- : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

### Skin protection

#### Hand protection

- : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

#### Body protection

- : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

<b>SDS Title:</b> Mitoxantrone Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000100	<b>Page Number:</b> Page 7 of 15
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> October 03, 2024	<b>Version number:</b> 1.0

## Section 8. Exposure controls/personal protection

- Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
- Respiratory protection** : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

## Section 9. Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

### Appearance

- Physical state** : Liquid.
- Color** : Blue. [Dark]
- Odor** : Not available.
- Odor threshold** : Not available.
- pH** : 3 to 4.5
- Melting point** : Not available.
- Boiling point or initial boiling point and boiling range** : Not available.
- Flash point** : Not available.
- Evaporation rate** : Not available.
- Flammability** : Not available.
- Lower and upper explosion limit/flammability limit** : Not available.
- Vapor pressure** :

Ingredient name	Vapor Pressure at 20°C			Vapor pressure at 50°C		
	mm Hg	kPa	Method	mm Hg	kPa	Method
Water	17.5	2.3		92.258	12.3	

- Relative vapor density** : Not available.
- Relative density** : Not available.
- Density** : 0.975 to 1.035 g/cm<sup>3</sup>
- Solubility(ies)** :

Media	Result
water	Soluble

- Miscible with water** : Yes.
- Partition coefficient: n-octanol/water** : Not applicable.
- Auto-ignition temperature** : Not available.
- Decomposition temperature** : Not available.





Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

<b>SDS Title:</b> Mitoxantrone Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000100	<b>Page Number:</b> Page 8 of 15
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> October 03, 2024	<b>Version number:</b> 1.0

## Section 9. Physical and chemical properties

<b>SADT</b>	: Not available.
<b>Viscosity</b>	: Dynamic (room temperature): Not available. Kinematic (room temperature): Not available. Kinematic (40°C (104°F)): Not available.
<b>Flow time (ISO 2431)</b>	: Not available.
<b>Particle characteristics</b>	
<b>Median particle size</b>	: Not applicable.
<b>Other information</b>	
<b>Physical/chemical properties comments</b>	: No additional information.

## Section 10. Stability and reactivity

<b>Reactivity</b>	: No specific test data related to reactivity available for this product or its ingredients.
<b>Chemical stability</b>	: The product is stable.
<b>Possibility of hazardous reactions</b>	: Under normal conditions of storage and use, hazardous reactions will not occur. Under normal conditions of storage and use, hazardous polymerization will not occur.
<b>Conditions to avoid</b>	: No specific data.
<b>Incompatible materials</b>	: No specific data.
<b>Hazardous decomposition products</b>	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## Section 11. Toxicological information

### Information on toxicological effects

#### Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
sodium chloride 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthraquinone dihydrochloride	LD50 Oral	Rat	3000 mg/kg	-
	LD50 Dermal	Rabbit	125 mg/kg	-
	LD50 Dermal	Rat	1640 mg/kg	-
	LD50 Oral	Rat	682 mg/kg	-
acetic acid	LC50 Inhalation Vapor	Rat	11000 mg/m <sup>3</sup>	4 hours

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.



<b>SDS Title:</b> Mitoxantrone Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000100	<b>Page Number:</b> Page 9 of 15
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> October 03, 2024	<b>Version number:</b> 1.0

## Section 11. Toxicological information

sodium acetate	LD50 Dermal LD50 Oral LD50 Oral	Rabbit Rat Rat	1060 mg/kg 3310 mg/kg 3530 mg/kg	- - -
----------------	---------------------------------------	----------------------	----------------------------------------	-------------

### Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
sodium chloride	Eyes - Moderate irritant	Rabbit	-	10 mg	-
	Eyes - Moderate irritant	Rabbit	-	24 hours 100 mg	-
	Skin - Mild irritant	Rabbit	-	24 hours 500 mg	-
acetic acid	Eyes - Mild irritant	Rabbit	-	0.5 minutes 5 mg	-
	Skin - Mild irritant	Rabbit	-	24 hours 50 mg	-
	Skin - Severe irritant	Rabbit	-	525 mg	-

### Sensitization

Not available.

### Mutagenicity

**Conclusion/Summary** : Not available.

### Carcinogenicity

**Conclusion/Summary** : Not available.

### Reproductive toxicity

**Conclusion/Summary** : Not available.

### Teratogenicity

**Conclusion/Summary** : Not available.

### Specific target organ toxicity (single exposure)

Not available.

### Specific target organ toxicity (repeated exposure)

Not available.

### Aspiration hazard

Not available.

**Information on the likely routes of exposure** : Routes of entry anticipated: Oral, Dermal, Inhalation, Eyes.

### Potential acute health effects

**Eye contact** : No known significant effects or critical hazards.

**Inhalation** : No known significant effects or critical hazards.

**Skin contact** : No known significant effects or critical hazards.

**Ingestion** : No known significant effects or critical hazards.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

<b>SDS Title:</b> Mitoxantrone Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000100	<b>Page Number:</b> Page 10 of 15
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> October 03, 2024	<b>Version number:</b> 1.0

## Section 11. Toxicological information

### Symptoms related to the physical, chemical and toxicological characteristics

- Eye contact** : No specific data.
- Inhalation** : Adverse symptoms may include the following:  
reduced fetal weight  
increase in fetal deaths  
skeletal malformations
- Skin contact** : Adverse symptoms may include the following:  
reduced fetal weight  
increase in fetal deaths  
skeletal malformations
- Ingestion** : Adverse symptoms may include the following:  
reduced fetal weight  
increase in fetal deaths  
skeletal malformations

### Delayed and immediate effects and also chronic effects from short and long term exposure

#### Short term exposure

- Potential immediate effects** : Not available.
- Potential delayed effects** : Not available.

#### Long term exposure

- Potential immediate effects** : Not available.
- Potential delayed effects** : Not available.

#### Potential chronic health effects

- General** : No known significant effects or critical hazards.
- Carcinogenicity** : No known significant effects or critical hazards.
- Mutagenicity** : May cause genetic defects.
- Reproductive toxicity** : May damage fertility or the unborn child.

### Numerical measures of toxicity

#### Acute toxicity estimates

Product/ingredient name	Oral (mg/kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapors) (mg/l)	Inhalation (dusts and mists) (mg/l)
sodium chloride	3000	N/A	N/A	N/A	N/A
1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthraquinone dihydrochloride	682	125	N/A	N/A	N/A
acetic acid	3310	1060	N/A	11	N/A
sodium acetate	3530	N/A	N/A	N/A	N/A

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.

SDS Title: Mitoxantrone Injection, USP Safety Data Sheet	SDS Number: SDS-000100	Page Number: Page 11 of 15
Function: Regulatory Affairs	Effective Date: October 03, 2024	Version number: 1.0

## Section 11. Toxicological information

## Section 12. Ecological information

### Toxicity

Product/ingredient name	Result	Species	Exposure
sodium chloride	Acute EC50 4.74 g/L Fresh water	Algae - <i>Chlamydomonas reinhardtii</i>	96 hours
	Acute EC50 28.85 mg/dm3 Fresh water	Algae - <i>Selenastrum capricornutum</i>	72 hours
	Acute EC50 519.6 mg/l Fresh water	Crustaceans - <i>Cypris subglobosa</i>	48 hours
	Acute EC50 402.6 mg/l Fresh water	Daphnia - <i>Daphnia magna</i>	48 hours
	Acute IC50 6.87 g/L Fresh water	Aquatic plants - <i>Lemna minor</i>	96 hours
	Acute LC50 1000000 µg/l Fresh water	Fish - <i>Morone saxatilis</i> - Larvae	96 hours
	Chronic LC10 781 mg/l Fresh water	Crustaceans - <i>Hyalella azteca</i> - Juvenile (Fledgling, Hatchling, Weanling)	3 weeks
	Chronic NOEC 6 g/L Fresh water	Aquatic plants - <i>Lemna minor</i>	96 hours
	Chronic NOEC 0.314 g/L Fresh water	Daphnia - <i>Daphnia pulex</i>	21 days
	Chronic NOEC 100 mg/l Fresh water	Fish - <i>Gambusia holbrooki</i> - Adult	8 weeks
acetic acid	Acute EC50 65000 µg/l Fresh water	Daphnia - <i>Daphnia magna</i> - Neonate	48 hours
sodium acetate	Acute LC50 32 mg/l Marine water	Crustaceans - <i>Artemia salina</i>	48 hours
	Acute LC50 75 ppm Fresh water	Fish - <i>Lepomis macrochirus</i>	96 hours
	Acute EC50 >1000 mg/l Marine water	Algae - <i>Skeletonema costatum</i>	72 hours
	Acute EC50 >919 mg/l Fresh water	Daphnia - <i>Daphnia magna</i>	48 hours
	Acute LC50 >1000 mg/l Fresh water	Fish - <i>Lepomis macrochirus</i>	96 hours
	Acute NOEC 1000 mg/l Marine water	Algae - <i>Skeletonema costatum</i>	72 hours

**Conclusion/Summary** : Not available.

### Persistence and degradability

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
acetic acid	-	-	Readily
sodium acetate	-	-	Readily

### Bioaccumulative potential

Product/ingredient name	LogP <sub>ow</sub>	BCF	Potential
Water	-1.38	-	Low
acetic acid	-0.17	3.16	Low
sodium acetate	-3.72	-	Low

### Mobility in soil

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.

<b>SDS Title:</b> Mitoxantrone Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000100	<b>Page Number:</b> Page 12 of 15
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> October 03, 2024	<b>Version number:</b> 1.0

## Section 12. Ecological information

**Soil/water partition coefficient ( $K_{oc}$ )** : Not available.

**Other adverse effects** : No known significant effects or critical hazards.

## Section 13. Disposal considerations

**Disposal methods** : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

## Section 14. Transport information

	<b>DOT Classification</b>	<b>IMDG</b>	<b>IATA</b>
<b>UN number</b>	Not regulated.	Not regulated.	Not regulated.
<b>UN proper shipping name</b>	-	-	-
<b>Transport hazard class(es)</b>	-	-	-
<b>Packing group</b>	-	-	-
<b>Environmental hazards</b>	No.	No.	No.

### Additional information

**Special precautions for user** : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

**Transport in bulk according to IMO instruments** : Not available.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

<b>SDS Title:</b> Mitoxantrone Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000100	<b>Page Number:</b> Page 13 of 15
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> October 03, 2024	<b>Version number:</b> 1.0

## Section 15. Regulatory information

**U.S. Federal regulations** : TSCA 8(a) CDR Exempt/Partial exemption: Not determined  
United States inventory (TSCA 8b): Not determined.  
Clean Water Act (CWA) 311: acetic acid

**Clean Air Act Section 112 (b) Hazardous Air Pollutants (HAPs)** : Not listed

**Clean Air Act Section 602 Class I Substances** : Not listed

**Clean Air Act Section 602 Class II Substances** : Not listed

**DEA List I Chemicals (Precursor Chemicals)** : Not listed

**DEA List II Chemicals (Essential Chemicals)** : Not listed

### SARA 302/304

#### Composition/information on ingredients

No products were found.

**SARA 304 RQ** : Not applicable.

### SARA 311/312

**Classification** : GERM CELL MUTAGENICITY - Category 1  
TOXIC TO REPRODUCTION - Category 1B

#### Composition/information on ingredients

Name	%	Classification
sodium chloride	<1	EYE IRRITATION - Category 2A
1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthraquinone dihydrochloride	≤0.3	ACUTE TOXICITY (oral) - Category 4 ACUTE TOXICITY (dermal) - Category 2 GERM CELL MUTAGENICITY - Category 1B TOXIC TO REPRODUCTION - Category 1B
acetic acid	≤0.1	FLAMMABLE LIQUIDS - Category 3 ACUTE TOXICITY (dermal) - Category 4 ACUTE TOXICITY (inhalation) - Category 4 SKIN CORROSION - Category 1A SERIOUS EYE DAMAGE - Category 1 HNOC - Corrosive to digestive tract [severe] HNOC - Corrosive to respiratory tract [severe]
sodium acetate	≤0.1	COMBUSTIBLE DUSTS

### SARA 313

Not applicable.

### State regulations

**Massachusetts** : None of the components are listed.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

SDS Title: Mitoxantrone Injection, USP Safety Data Sheet	SDS Number: SDS-000100	Page Number: Page 14 of 15
Function: Regulatory Affairs	Effective Date: October 03, 2024	Version number: 1.0

## Section 15. Regulatory information

**New York** : None of the components are listed.

**New Jersey** : None of the components are listed.

**Pennsylvania** : None of the components are listed.

**California Prop. 65**

**⚠ WARNING:** This product can expose you to Mitoxantrone hydrochloride, which is known to the State of California to cause cancer and birth defects or other reproductive harm. For more information go to [www.P65Warnings.ca.gov](http://www.P65Warnings.ca.gov).

Ingredient name	No significant risk level	Maximum acceptable dosage level
Mitoxantrone hydrochloride	-	-

### International regulations

**Chemical Weapon Convention List Schedules I, II & III Chemicals**

Not listed.

**Montreal Protocol**

Not listed.

**Stockholm Convention on Persistent Organic Pollutants**

Not listed.

**Rotterdam Convention on Prior Informed Consent (PIC)**

Not listed.

**UNECE Aarhus Protocol on POPs and Heavy Metals**

Not listed.

## Section 16. Other information

### Hazardous Material Information System (U.S.A.)

Health	*	0
Flammability		0
Physical hazards		0

Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. Although HMIS® ratings and the associated label are not required on SDSs or products leaving a facility under 29 CFR 1910.1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS® program. HMIS® is a registered trademark and service mark of the American Coatings Association, Inc.

The customer is responsible for determining the PPE code for this material. For more information on HMIS® Personal Protective Equipment (PPE) codes, consult the HMIS® Implementation Manual.

### National Fire Protection Association (U.S.A.)

<b>SDS Title:</b> Mitoxantrone Injection, USP Safety Data Sheet	<b>SDS Number:</b> SDS-000100	<b>Page Number:</b> Page 15 of 15
<b>Function:</b> Regulatory Affairs	<b>Effective Date:</b> October 03, 2024	<b>Version number:</b> 1.0

## Section 16. Other information



### Procedure used to derive the classification

Classification	Justification
GERM CELL MUTAGENICITY - Category 1 TOXIC TO REPRODUCTION - Category 1B	Calculation method Calculation method

### History

<b>Date of issue/Date of revision</b>	: 10/03/2024
<b>Date of previous issue</b>	: No previous validation
<b>Version</b>	: 1.0
<b>Prepared by</b>	: Sphera Solutions
<b>Key to abbreviations</b>	: ATE = Acute Toxicity Estimate AMP = Acceptable maximum peak above the acceptable ceiling concentration for an 8-hr shift BCF = Bioconcentration Factor GHS = Globally Harmonized System of Classification and Labelling of Chemicals IATA = International Air Transport Association IBC = Intermediate Bulk Container IMDG = International Maritime Dangerous Goods LogPow = logarithm of the octanol/water partition coefficient MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution) N/A = Not available UN = United Nations
<b>References</b>	: HCS (U.S.A.)- Hazard Communication Standard International transport regulations

Indicates information that has changed from previously issued version.

### Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.